Metabolic brain mapping in Alzheimer's disease using proton magnetic resonance spectroscopy

被引:45
作者
Lazeyras, F
Charles, HC
Tupler, LA
Erickson, R
Boyko, OB
Krishnan, KRR
机构
[1] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA
[3] Univ Hosp Geneva, Div Radiodiagnost, Geneva, Switzerland
[4] Temple Univ, Dept Radiol, Philadelphia, PA 19122 USA
关键词
Alzheimer's disease; myo-inositol; H-1-MRS; physicochemical;
D O I
10.1016/S0925-4927(98)00010-9
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Alzheimer's disease (AD) is a progressive disorder associated with disruption of neuronal function and neuronal loss. N-acetylaspartate (NAA) is a marker of neuronal content and can be assessed using proton (H-1) magnetic resonance spectroscopy (MRS). We utilized H-1-MRS (two-dimensional chemical-shift imaging) to assess amplitudes and areas of NAA, as well as choline moieties (Cho), creatine (Cr) and myo-inositol (mI), in 15 AD patients compared with 14 control subjects. Voxels were classified as predominantly cortical gray matter (CGM), subcortical gray matter (SGM), or white matter (WM). Compared with control subjects, AD patients exhibited decreased NAA/Cho and NAA/Cr amplitudes, whereas an increase was observed in Cho/Cr and in amplitude ratios involving mi. Area ratios were significant in the same direction for NAA/Cho, NAA/Cr, mI/Cr and mI/NAA. No significant effects of tissue type were observed; however, significant group x tissue type interactions were noted for Cho/Cr and mI/Cr amplitudes. Our study confirms that H-1-MRS can identify distinct physicochemical alterations in AD patients, reflecting membrane changes and diminished neuronal function. These alterations can be used as longitudinal markers for the disease. (C) 1998 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:95 / 106
页数:12
相关论文
共 62 条
[1]  
ANSELL GB, 1975, CHOLINERGIC MECH, P117
[2]  
BALERIAUX D, 1989, ACTA NEUROL BELG, V89, P156
[3]   N-ACETYL-L-ASPARTIC ACID - A LITERATURE-REVIEW OF A COMPOUND PROMINENT IN H-1-NMR SPECTROSCOPIC STUDIES OF BRAIN [J].
BIRKEN, DL ;
OLDENDORF, WH .
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 1989, 13 (01) :23-31
[4]   H-1-MR-SPECTROSCOPIC IMAGING IN PATIENTS WITH ALZHEIMERS-DISEASE [J].
BLOCK, W ;
TRABER, F ;
KUHL, CK ;
FRIC, M ;
KELLER, E ;
LAMERICHS, R ;
RINK, H ;
MOLLER, HJ ;
SCHILD, HH .
FORTSCHRITTE AUF DEM GEBIETE DER RONTGENSTRAHLEN UND DER NEUEN BILDGEBENDEN VERFAHREN, 1995, 163 (03) :230-237
[5]   LEVELS OF PHOSPHOLIPID CATABOLIC INTERMEDIATES, GLYCEROPHOSPHOCHOLINE AND GLYCEROPHOSPHOETHANOLAMINE, ARE ELEVATED IN BRAINS OF ALZHEIMERS-DISEASE BUT NOT OF DOWNS-SYNDROME PATIENTS [J].
BLUSZTAJN, JK ;
GONZALEZCOVIELLA, IL ;
LOGUE, M ;
GROWDON, JH ;
WURTMAN, RJ .
BRAIN RESEARCH, 1990, 536 (1-2) :240-244
[6]   ALZHEIMER DEMENTIA - QUANTIFICATION OF ENERGY-METABOLISM AND MOBILE PHOSPHOESTERS WITH P-31 NMR-SPECTROSCOPY [J].
BOTTOMLEY, PA ;
COUSINS, JP ;
PENDREY, DL ;
WAGLE, WA ;
HARDY, CJ ;
EAMES, FA ;
MCCAFFREY, RJ ;
THOMPSON, DA .
RADIOLOGY, 1992, 183 (03) :695-699
[7]   QUANTIFICATION OF GLUTAMATE, GLUTAMINE, AND OTHER METABOLITES IN INVIVO PROTON NMR-SPECTROSCOPY [J].
BOVEE, WMMJ .
NMR IN BIOMEDICINE, 1991, 4 (02) :81-84
[8]  
Braak H, 1990, Fortschr Med, V108, P621
[9]   MUSCARINIC MOBILIZATION OF CHOLINE IN RAT CEREBRAL-CORTEX DOES NOT INVOLVE ALTERATIONS OF BLOOD-BRAIN BARRIER [J].
BREHM, R ;
CORRADETTI, R ;
KRAHN, V ;
LOFFELHOLZ, K ;
PEPEU, G .
BRAIN RESEARCH, 1985, 345 (02) :306-314
[10]   MUSCARINIC MOBILIZATION OF CHOLINE IN RAT-BRAIN INVIVO AS SHOWN BY THE CEREBRAL ARTERIOVENOUS DIFFERENCE OF CHOLINE [J].
BREHM, R ;
LINDMAR, R ;
LOFFEHOLZ, K .
JOURNAL OF NEUROCHEMISTRY, 1987, 48 (05) :1480-1485